Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,70€(−35,85%). Der Median liegt bei +1,70€(−35,85%).

Kaufen	4
Halten	0
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	0 / 18
Levermann-Strategie	2 / 13

News

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
Cohen and Associates is a highly respected neuropsychiatry clinic in western Florida Cohen to serve as foundational clinic in the Sarasota - Bradenton area of Florida Acquisition expected to be immediately accretive to revenue and EBITDA MIAMI , June 26, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the signing of a binding Letter of Intent (the "LOI") to purchase a 49% interest in Cohen and Associates, LLC ("Cohen"), founded by Dr. Rebecca Cohen. Cohen is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida.» Mehr auf prnewswire.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)
Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025 Application under CNPV program is accretive to already-filed Abbreviated New Drug Application (ANDA) for preservative-free ketamine, with proprietary formulation under priority review request Company has received and complied with FDA information request for updated drug ingredient and label information on NRX-100 Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine WILMINGTON, Del.» Mehr auf prnewswire.com
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
WILMINGTON, Del. , June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced a strategic investor relations partnership with astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte NRX Pharmaceuticals einen Umsatz von 0,00€ und ein Nettoeinkommen von −5,10 Mio€

(EUR)	März 2025	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	100,00%
Nettoeinkommen	−5,10 Mio	15,77%
EBITDA	−5,10 Mio	12,68%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+51,74 Mio€
Anzahl Aktien	19,50 Mio
52 Wochen-Hoch/Tief	+5,09€ - +0,93€
Dividenden	Nein
Beta	1,55
KGV (PE Ratio)	−2,13
KGWV (PEG Ratio)	−0,13
KBV (PB Ratio)	−2,04
KUV (PS Ratio)	+15.261,41

Unternehmensprofil

NRX Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen in der klinischen Phase und entwickelt neuartige Therapeutika für die Behandlung von Erkrankungen des zentralen Nervensystems und lebensbedrohlichen Lungenkrankheiten. Zu seinen Produkten gehören ZYESAMI, ein Prüfpräparat, das eine klinische Studie der Phase IIb/III zur Behandlung von COVID-19-bedingtem Atemversagen abgeschlossen hat, sowie die oralen Therapeutika NRX-100 und NRX-101 zur Behandlung bipolarer Depressionen bei Patienten mit akuter Suizidalität und subakuten Suizidgedanken und -verhaltensweisen. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Sitz in Wilmington, Delaware.